Larimar Therapeutics, Inc. (LRMR)

In the past six months, Larimar Therapeutics' stock has experienced fluctuations, with a gain of 9.77% on February 6, 2026, but an 8.67% fall over the preceding 10 days. The stock's 52-week trading range has been between $1.61 and $5.37. Insider sentiment has been positive, with high-impact open-market purchases from 10 different insiders over the last year, and insider ownership increased by 57.84% in the 90 days leading up to January 29, 2026. The company reported its Q3 2025 earnings on November 5, 2025, and Q2 2025 earnings on August 14, 2025. An Annual General Meeting was held on May 13, 2025.

There is no specific information available indicating demand seasonality for Larimar Therapeutics, Inc.'s products or services. Demand for its product candidates is primarily driven by clinical trial progress, regulatory milestones, and the needs of the patient population, rather than typical seasonal consumer patterns.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, operating within the Healthcare sector and Biotechnology industry. The company utilizes a novel cell-penetrating peptide (CPP) technology platform, with its primary product candidate being nomlabofusp, designed to deliver human frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA). Nomlabofusp has received designations such as Rare Pediatric Disease, Fast Track, orphan drug status from the FDA and EMA, and PRIME designation by the EMA. The company intends to use its intracellular delivery platform to develop other fusion proteins for additional rare diseases caused by deficiencies in intracellular proteins.

Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania, United States.

Larimar Therapeutics has generally received a "Buy" or "Moderate Buy" consensus rating from analysts, driven by promising clinical results for CTI-1601, which showed a median increase in frataxin expression and an improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) in its Phase 2 clinical program. However, the company's financial outlook has faced some challenges, including a significant decrease in the FY29 revenue estimate, and there have been indications of decreasing investor sentiment, as evidenced by a recent increase in short interest by 4.22%.

Larimar Therapeutics, Inc. has 217 institutional owners and shareholders, holding a total of 89,383,824 shares. Major institutional shareholders include Deerfield Management Company, L.p., Ra Capital Management, L.p., and Blue Owl Capital Holdings LP. Principal insider shareholders include Director James E Flynn, Director Thomas Edward Hamilton, and President and CEO Carole Ben-Maimon. Insider ownership constitutes approximately 10.86% of the company's equity base.